CL2014000053A1 - Use of a composition containing a non-polymeric oxygen carrier of tetrameric hemoglobin crosslinked with an undetectable concentration of dimers for the manufacture of a medicament to reduce the recurrence of cancerous tumors and / or minimize the metastasis of tumor cells in a mammal; composition comprising said hemoglobin. - Google Patents

Use of a composition containing a non-polymeric oxygen carrier of tetrameric hemoglobin crosslinked with an undetectable concentration of dimers for the manufacture of a medicament to reduce the recurrence of cancerous tumors and / or minimize the metastasis of tumor cells in a mammal; composition comprising said hemoglobin.

Info

Publication number
CL2014000053A1
CL2014000053A1 CL2014000053A CL2014000053A CL2014000053A1 CL 2014000053 A1 CL2014000053 A1 CL 2014000053A1 CL 2014000053 A CL2014000053 A CL 2014000053A CL 2014000053 A CL2014000053 A CL 2014000053A CL 2014000053 A1 CL2014000053 A1 CL 2014000053A1
Authority
CL
Chile
Prior art keywords
hemoglobin
composition
dimers
metastasis
recurrence
Prior art date
Application number
CL2014000053A
Other languages
Spanish (es)
Inventor
Sui Yi Kwok
Bing Lou Wong
Sze Hang Lau
Original Assignee
Billion King Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Billion King Int Ltd filed Critical Billion King Int Ltd
Publication of CL2014000053A1 publication Critical patent/CL2014000053A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014000053A 2011-07-11 2014-01-09 Use of a composition containing a non-polymeric oxygen carrier of tetrameric hemoglobin crosslinked with an undetectable concentration of dimers for the manufacture of a medicament to reduce the recurrence of cancerous tumors and / or minimize the metastasis of tumor cells in a mammal; composition comprising said hemoglobin. CL2014000053A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/179,590 US8048856B1 (en) 2010-06-23 2011-07-11 Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition

Publications (1)

Publication Number Publication Date
CL2014000053A1 true CL2014000053A1 (en) 2014-08-29

Family

ID=47506871

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000053A CL2014000053A1 (en) 2011-07-11 2014-01-09 Use of a composition containing a non-polymeric oxygen carrier of tetrameric hemoglobin crosslinked with an undetectable concentration of dimers for the manufacture of a medicament to reduce the recurrence of cancerous tumors and / or minimize the metastasis of tumor cells in a mammal; composition comprising said hemoglobin.

Country Status (17)

Country Link
US (1) US8048856B1 (en)
EP (1) EP2731619A4 (en)
JP (1) JP6100252B2 (en)
KR (1) KR101925346B1 (en)
CN (1) CN103687609B (en)
AP (1) AP3840A (en)
AU (1) AU2012282692B2 (en)
BR (1) BR112014000535A2 (en)
CA (1) CA2841445C (en)
CL (1) CL2014000053A1 (en)
EA (1) EA201400020A1 (en)
HK (1) HK1192714A1 (en)
MA (1) MA35279B1 (en)
MX (1) MX346736B (en)
MY (1) MY169908A (en)
WO (1) WO2013009790A2 (en)
ZA (1) ZA201400698B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849448C (en) 2011-09-06 2020-03-24 Bing Lou Wong Oral delivery for hemoglobin based oxygen carriers
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
WO2014186301A1 (en) * 2013-05-13 2014-11-20 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
US9225652B2 (en) * 2013-12-05 2015-12-29 Huawei Technologies Co., Ltd. Framework for traffic engineering in software defined networking
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US9763889B2 (en) 2015-06-29 2017-09-19 Billion King International Ltd. Oral delivery system for hemoglobin based oxygen carriers
US10052290B2 (en) 2016-02-04 2018-08-21 Billion King International Ltd. Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2548671B1 (en) 1983-07-07 1986-05-02 Merieux Inst PROCESS FOR THE PREPARATION OF A GLOBIN FROM HEMOGLOBIN AND A GLOBIN OBTAINED BY THIS PROCESS
US4831012A (en) 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
USRE34271E (en) 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
JPH0750329B2 (en) 1986-06-23 1995-05-31 富士写真フイルム株式会社 Image forming material
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
US5753616A (en) 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5955581A (en) 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5189146A (en) 1987-05-05 1993-02-23 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Pasteurizable, freeze-driable hemoglobin-based blood substitute
US5439882A (en) 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
US5344393A (en) 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5387672A (en) * 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US5840851A (en) 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5804561A (en) 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5741893A (en) 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
JP3161604B2 (en) 1994-05-13 2001-04-25 プラズマセレクト ゲーエムベーハー テテロウ A sterile, pyrogen-free column that binds proteins in the blood to remove and remove substances in the blood
SE9500724D0 (en) 1994-06-23 1995-02-24 Pharmacia Ab Filtration
US5895810A (en) 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US6288027B1 (en) 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5691453A (en) 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
US5865784A (en) 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
EP0863918A1 (en) 1995-11-30 1998-09-16 Somatogen Inc. Method for control of functionality during cross-linking of hemoglobins
ES2205074T3 (en) 1996-03-21 2004-05-01 KOBUSCH-SENGEWALD GMBH & CO.KG MULTI-PATH FILM AND PROCEDURE FOR ITS PRODUCTION, AND ITS USE.
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
US5814601A (en) 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
JP4583510B2 (en) 1997-02-28 2010-11-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Methods and compositions for optimization of oxygen transport by cell-free systems
AU745209B2 (en) 1998-01-06 2002-03-14 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US6977140B1 (en) 1998-09-29 2005-12-20 Organ Recovery Systems, Inc. Method for maintaining and/or restoring viability of organs
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
DE10031744A1 (en) * 2000-06-29 2002-01-17 Sanguibio Tech Ag Mammalian hemoglobins compatible with blood plasma, crosslinked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, their production and their use
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
JP4260417B2 (en) 2001-05-23 2009-04-30 ノバルティス アクチエンゲゼルシャフト System and method for transporting and deoxygenating solutions
US7038016B2 (en) 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
ES2360215T3 (en) 2002-12-23 2011-06-01 Albert Einstein College Of Medicine Of Yeshiva University HEMOGLOBINS PEGILATED NON HYPERTENSIVE AND ITS PREPARATION PROCEDURES.
BRPI0407106A (en) 2003-01-29 2006-01-24 Northfield Lab Reduced Tetramer Cured Hemoglobin Solutions and Method for Preparation
US7655392B2 (en) 2004-10-29 2010-02-02 Cerus Corporation Quenching methods for red blood cell inactivation process
US7759306B2 (en) 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
AU2008266938A1 (en) 2007-06-13 2008-12-24 Opk Biotech Llc Targeted oxygen delivery via intravenous or intra-arterial infusion of oxygenated polymerized hemoglobin solutions
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
HK1192714A1 (en) 2014-08-29
CA2841445A1 (en) 2013-01-17
EP2731619A4 (en) 2015-03-11
JP2014520850A (en) 2014-08-25
EP2731619A2 (en) 2014-05-21
EA201400020A1 (en) 2014-06-30
MX2014000355A (en) 2015-01-27
KR20140054038A (en) 2014-05-08
CA2841445C (en) 2019-02-26
US8048856B1 (en) 2011-11-01
AP2014007422A0 (en) 2014-02-28
ZA201400698B (en) 2015-09-30
JP6100252B2 (en) 2017-03-22
BR112014000535A2 (en) 2017-10-03
AP3840A (en) 2016-09-30
KR101925346B1 (en) 2018-12-05
MA35279B1 (en) 2014-07-03
CN103687609B (en) 2016-07-20
MY169908A (en) 2019-06-14
AU2012282692A1 (en) 2014-01-30
CN103687609A (en) 2014-03-26
MX346736B (en) 2017-03-30
NZ619782A (en) 2016-09-30
WO2013009790A2 (en) 2013-01-17
AU2012282692B2 (en) 2017-04-27
WO2013009790A3 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
CL2014000053A1 (en) Use of a composition containing a non-polymeric oxygen carrier of tetrameric hemoglobin crosslinked with an undetectable concentration of dimers for the manufacture of a medicament to reduce the recurrence of cancerous tumors and / or minimize the metastasis of tumor cells in a mammal; composition comprising said hemoglobin.
UY33647A (en) ? AGENTS OF UNION TO CD33 ?.
MX2022013713A (en) Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane.
CR20110558A (en) ANTI-FcRH5 ANTIBODIES AND IMMUNOCATE PLAYERS AND METHODS OF USE
UY35082A (en) OXYGEN CARRIER SUBSTANCE BASED ON HEMOGLOBIN CONTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER AND THE PREVENTION OF CANCER RECURRENCE
PH12014501639A1 (en) Pharmaceutical compositions and methods
ECSP14012726A (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
AU2012335543A8 (en) HER3 antibodies and uses thereof
EA201590671A1 (en) COMBINATION OF ANTIBODIES TO KIR AND ANTIBODIES TO PD-1 FOR THE TREATMENT OF MALIGNANT TUMOR
HUE049886T2 (en) Compositions of tumor specific neoantigens for use in treating tumours
EA201400991A1 (en) COMBINED THERAPY USING ANTIBODIES TO HUMAN CSF-1R AND ITS APPLICATIONS
EA033115B1 (en) Anti-cd38 antibodies and fusion proteins with attenuated interferon alpha-2b
IN2015DN03795A (en)
CL2012002317A1 (en) Compounds derived from thienopyrimidines, knase inhibitors mnk1 / mnk2; pharmaceutical composition; and its use for the treatment or prophylaxis of metabolic diseases, such as diabetes, kidney damage, cancer, inflammatory diseases, among others.
BR112013001122A2 (en) therapeutic active compositions and their method of use
CL2013001138A1 (en) Composition comprising bispecific cd19xcd3 antibody to treat tumor mass of lymph node tissue and / or extranodal lymphoma caused by diffuse large cell lymphoma b (lbdcg); pharmaceutical kit; Use of the composition.
IN2014CN04482A (en)
CL2011001255A1 (en) Pharmaceutical combinations comprising an antibody that specifically recognizes cd38 and at least vincristine; and use of the antibody that specifically recognizes cd38 for the treatment of cancer.
CL2012002328A1 (en) Isolated anti-tat419 antibody that inhibits cell proliferation; nucleic acid encoding it; cell that produces it; method to identify antibodies that bind an antigenic epitope tat419; method to inhibit the proliferation of a cell expressing a tat419 peptide; and its use in the treatment of cancer tumors.
CL2013001324A1 (en) Kit comprising ec145 and one or more additional chemotherapeutic agents; Use to treat cancer.
BR112013003579A2 (en) adenovirus, cells, and methods to treat cancer
EP2703710A4 (en) Polycarbonate resin composition for transparent body, as well as transparent body and surface light source formed from same
CO6741197A2 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
PT2768313E (en) Composition for use in the promotion of magnesium absorption and/or magnesium retention
AR087245A1 (en) OXYGEN ABSORBENT CONTAINING CARBON WITH HIGH WATER ACTIVITY